AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24251556 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational physiotherapy (E group)
Number of subjects: 31
Study 24251556 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 22088556 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3480 (5 mg, 20 mg, and 35/100 mg depending on CYP2D6 metabolic status)
Number of subjects: 440
Study 22088556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study 21053620 — intervention group
Group type: EXPERIMENTAL
Intervention: Qufeng Zhidong Recipe (TCM group)
Number of subjects: 61
Study 21053620 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol and trihexyphenidyl (Western medicine group)
Number of subjects: 61
Study 17639278 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthognathic surgery
Number of subjects: 102
Study 16290975 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhospital educational intervention delivered by a multidisciplinary team
Number of subjects: 134
Study 16290975 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 134
Study 12165970 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week stress management treatment
Number of subjects: 0
Study 12165970 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo intervention
Number of subjects: 0
Study 10066999 — intervention group
Group type: EXPERIMENTAL
Intervention: Aversive conditioning to explicit and contextual cues
Number of subjects: 0
Study 7720340 — intervention group
Group type: EXPERIMENTAL
Intervention: Right atrioventricular pacing at a rate of 150 impulses/min
Number of subjects: 10
Study 1759830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten (CFB) single oral dose of 4.5 or 9.0 mg/kg
Number of subjects: 49
Study 1759830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten (CFB) in children from 0.5 to <= 5 years of age
Number of subjects: 49
Study 1759830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten (CFB) in children > 10 years of age
Number of subjects: 49
Study 1759830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten (CFB) in infants
Number of subjects: 49
Study 1759830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten (CFB) in 19 subjects
Number of subjects: 49
Study 6818599 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol administrations
Number of subjects: 0
Study 6818599 — intervention group
Group type: COMPARATOR
Intervention: Placebo administrations
Number of subjects: 0
Study 6818599 — intervention group
Group type: EXPERIMENTAL
Intervention: Test dose of ethanol
Number of subjects: 0
Study 30669469 — intervention group
Group type: EXPERIMENTAL
Intervention: 140 g of whole blueberries
Number of subjects: 17
Study 30669469 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (matched for calories, sugars, and fiber)
Number of subjects: 17
Study 30306796 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational health education program
Number of subjects: 70
Study 30306796 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 70
Study 26439782 — intervention group
Group type: EXPERIMENTAL
Intervention: Squat training group (SQ)
Number of subjects: 78
Study 26439782 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg-press training group (LP)
Number of subjects: 78
Study 26439782 — intervention group
Group type: COMPARATOR
Intervention: Control group for SQ
Number of subjects: 78
Study 26439782 — intervention group
Group type: COMPARATOR
Intervention: Control group for LP
Number of subjects: 78
Study 23903975 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 129
Study 23903975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 21931983 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued double-step saccade task
Number of subjects: 0
Study 21931983 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccade execution
Number of subjects: 0
Study 21931983 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial visual and motor processing prior to saccade execution
Number of subjects: 0
Study 17878209 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with methotrexate and ciclosporine
Number of subjects: 160
Study 17878209 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with methotrexate and placebo-ciclosporine
Number of subjects: 160
Study 15894441 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 30
Study 12605235 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical alprostadil 0.05 mg
Number of subjects: 303
Study 12605235 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical alprostadil 0.1 mg
Number of subjects: 303
Study 12605235 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical alprostadil 0.2 mg
Number of subjects: 303
Study 12605235 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical alprostadil 0.3 mg
Number of subjects: 303
Study 12605235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study 10838535 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioplegic group with 42 mmol/L glucose and 10 IU/L insulin
Number of subjects: 56
Study 10838535 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioplegic group with 84 mmol/L glucose and 10 IU/L insulin
Number of subjects: 56
Study 10838535 — intervention group
Group type: COMPARATOR
Intervention: Cardioplegic group with 42 mmol/L glucose without insulin
Number of subjects: 56
Study 10838535 — intervention group
Group type: COMPARATOR
Intervention: Cardioplegic group with 84 mmol/L glucose without insulin
Number of subjects: 56
Study 9087577 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle training for 4 weeks
Number of subjects: 13
Study 9087577 — intervention group
Group type: COMPARATOR
Intervention: Normal sedentary activity for 4 weeks
Number of subjects: 13
Study 8482629 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy doses of < or = 54 Gy
Number of subjects: 302
Study 8482629 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy doses > or = 57.6 Gy
Number of subjects: 302
Study 8482629 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy doses > or = 63 Gy
Number of subjects: 302
Study 8482629 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy doses 57.6 Gy with a boost of 63 Gy
Number of subjects: 302
Study 8482629 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose escalation above 63 Gy at 1.8 Gy per day
Number of subjects: 302
Study 8482629 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall crude and actuarial 2‐year local‐regional recurrence rates
Number of subjects: 302
Study 3512351 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole once daily for 4 weeks
Number of subjects: 115
Study 3512351 — intervention group
Group type: COMPARATOR
Intervention: 30 mg omeprazole once daily for 4 weeks
Number of subjects: 115
Study 28975842 — intervention group
Group type: EXPERIMENTAL
Intervention: Two home visits to individualize home exercises
Number of subjects: 50
Study 28975842 — intervention group
Group type: COMPARATOR
Intervention: Usual care including weekly group exercise
Number of subjects: 50
Study 27624168 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 463
Study 27624168 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 463
Study 24837559 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic biliopancreatic diversion with duodenal switch (BPD/DS)
Number of subjects: 57
Study 24837559 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 57
Study 24837559 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 57
Study 22658785 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA (Neurally Adjusted Ventilatory Assist)
Number of subjects: 26
Study 22658785 — intervention group
Group type: COMPARATOR
Intervention: SIMV with PS (Synchronized Intermittent Mandatory Ventilation with Pressure Support)
Number of subjects: 26
Study 20642939 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic pre-conditioning (rIPC)
Number of subjects: 100
Study 20642939 — intervention group
Group type: COMPARATOR
Intervention: Control group (no limb ischemia)
Number of subjects: 100
Study 17989310 — intervention group
Group type: COMPARATOR
Intervention: Normal glycemia
Number of subjects: 5842
Study 17989310 — intervention group
Group type: COMPARATOR
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 5842
Study 17989310 — intervention group
Group type: COMPARATOR
Intervention: Impaired glucose tolerance (IGT)
Number of subjects: 5842
Study 17989310 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 5842
Study 17989310 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertriglyceridemia
Number of subjects: 5842
Study 17989310 — intervention group
Group type: EXPERIMENTAL
Intervention: Log fasting plasma glucose
Number of subjects: 5842
Study 17989310 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 5842
Study 17989310 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 5842
Study 17989310 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical inactivity
Number of subjects: 5842
Study 17989310 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of diabetes
Number of subjects: 5842
Study 17989310 — intervention group
Group type: EXPERIMENTAL
Intervention: Low education level
Number of subjects: 5842
Study 17989310 — intervention group
Group type: EXPERIMENTAL
Intervention: A1C
Number of subjects: 5842
Study 18721011 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel laparoscopic cholecystectomy (HS group=60 patients)
Number of subjects: 120
Study 18721011 — intervention group
Group type: COMPARATOR
Intervention: Clip and cautery laparoscopic cholecystectomy (C&C group=60 patients)
Number of subjects: 120
Study 18721011 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel laparoscopic cholecystectomy (HS group)
Number of subjects: 120
Study 18721011 — intervention group
Group type: COMPARATOR
Intervention: Clip and cautery laparoscopic cholecystectomy (C&C group)
Number of subjects: 120
Study 18721011 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 15580967 — intervention group
Group type: EXPERIMENTAL
Intervention: Opegan (Santen Pharmaceuticals, Osaka, Japan)
Number of subjects: 69
Study 15580967 — intervention group
Group type: COMPARATOR
Intervention: Soft-shell technique using Viscoat (Alcon Surgical, Fort Worth, TX)
Number of subjects: 69
Study 11336102 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 62
Study 11336102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 9228196 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (15 microg/kg i.v. loading dose followed by 0.15 microg/kg/min by i.v. infusion) with Noradrenaline (5 incremental doses of 10‐120 ng/kg/min)
Number of subjects: 6
Study 9228196 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (15 microg/kg i.v. loading dose followed by 0.15 microg/kg/min by i.v. infusion) with Tyramine (4 incremental doses of 5‐20 microg/kg/min)
Number of subjects: 6
Study 9228196 — intervention group
Group type: COMPARATOR
Intervention: Noradrenaline (5 incremental doses of 10‐120 ng/kg/min)
Number of subjects: 6
Study 9228196 — intervention group
Group type: COMPARATOR
Intervention: Tyramine (4 incremental doses of 5‐20 microg/kg/min)
Number of subjects: 6
Study 7962379 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin, 500 micrograms subcutaneously daily, with variable amounts of menopausal gonadotrophins for ovarian stimulation.
Number of subjects: 11
Study 2886561 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics alone
Number of subjects: 78
Study 2886561 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone plus SR oxprenolol
Number of subjects: 78
Study 2886561 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol alone
Number of subjects: 78
Study 2886561 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol alone
Number of subjects: 78
Study 2886561 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol followed by atenolol
Number of subjects: 78
Study 2886561 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal mass pretreatment)
Number of subjects: 78
Study 31558426 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (n=42)
Number of subjects: 87
Study 31558426 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n=45)
Number of subjects: 87
Study 30498184 — intervention group
Group type: EXPERIMENTAL
Intervention: WhatsApp usage for dentistry-related purposes
Number of subjects: 105
Study 26196527 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational anaesthetic video (8 minutes)
Number of subjects: 100
Study 26196527 — intervention group
Group type: COMPARATOR
Intervention: Standard verbal briefing on anaesthesia (8 minutes)
Number of subjects: 100
Study 25197669 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 IU r-LH for 4 days followed by 400 IU r-FSH after downregulation with daily GnRh agonist
Number of subjects: 43
Study 25197669 — intervention group
Group type: COMPARATOR
Intervention: Conventional cycles (historical control)
Number of subjects: 43
Study 22803101 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with mesalazine
Number of subjects: 0
Study 22803101 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with mesalazine and dalargin
Number of subjects: 0
Study 22803101 — intervention group
Group type: COMPARATOR
Intervention: Reference group (patients with irritable bowel syndrome)
Number of subjects: 0
Study 19565392 — intervention group
Group type: EXPERIMENTAL
Intervention: Lee Silverman Voice Treatment (LSVT)
Number of subjects: 10
Study 19565392 — intervention group
Group type: COMPARATOR
Intervention: Traditional dysarthria therapy
Number of subjects: 10
Study 17958845 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band UVB (NBUVB)
Number of subjects: 50
Study 17958845 — intervention group
Group type: COMPARATOR
Intervention: Psoralen and ultraviolet A (PUVA)
Number of subjects: 50
Study 16307694 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg at week 0 and week 2, followed by either placebo or infliximab (5 or 10 mg/kg) every 8 weeks or episodically on loss of response.
Number of subjects: 0
Study 16307694 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab treatment (5 or 10 mg/kg)
Number of subjects: 0
Study 12004211 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin (24 g daily for 3 weeks)
Number of subjects: 20
Study 12004211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10460604 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related mortality during induction and first remission of AML
Number of subjects: 341
Study 10460604 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection-related deaths
Number of subjects: 341
Study 10460604 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemorrhage-related deaths
Number of subjects: 341
Study 10460604 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac failure-related deaths
Number of subjects: 341
Study 7637747 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive spirometry (10 maximal inspirations every 2 hours during the day and while awake at night until pain subsided)
Number of subjects: 29
Study 7637747 — intervention group
Group type: COMPARATOR
Intervention: Nonspirometry (control group)
Number of subjects: 29
Study 7637747 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive spirometry (among patients with thoracic bone infarction)
Number of subjects: 29
Study 7637747 — intervention group
Group type: COMPARATOR
Intervention: Nonspirometry (among patients with thoracic bone infarction)
Number of subjects: 29
Study 2663953 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler examination
Number of subjects: 40
Study 2663953 — intervention group
Group type: COMPARATOR
Intervention: Venography
Number of subjects: 40
Study 1164639 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate 0.05% ointment and cream
Number of subjects: 0
Study 1164639 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate 0.05% ointment
Number of subjects: 0
Study 1164639 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone 1%
Number of subjects: 0
Study 1164639 — intervention group
Group type: COMPARATOR
Intervention: Fluocortolone 0.2%
Number of subjects: 0
Study 30476460 — intervention group
Group type: EXPERIMENTAL
Intervention: 16.2 g (270 mg I/mL)
Number of subjects: 52
Study 30476460 — intervention group
Group type: EXPERIMENTAL
Intervention: 16.0 g (320 mg I/mL)
Number of subjects: 52
Study 30476460 — intervention group
Group type: EXPERIMENTAL
Intervention: DECTA (both doses)
Number of subjects: 52
Study 28528472 — intervention group
Group type: EXPERIMENTAL
Intervention: iPTH assay 6 hours after surgery
Number of subjects: 150
Study 28528472 — intervention group
Group type: COMPARATOR
Intervention: Daily assay of serum calcium and phosphorus (Control)
Number of subjects: 150
Study 26425050 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 40
Study 26425050 — intervention group
Group type: COMPARATOR
Intervention: Desflurane anesthesia
Number of subjects: 40
Study 26425050 — intervention group
Group type: EXPERIMENTAL
Intervention: Both propofol and desflurane anesthesia
Number of subjects: 40
Study 23504925 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education combined with sessions of vigorous extracurricular physical activity (VEPA) for 7 weeks, consisting of 13 sessions.
Number of subjects: 54
Study 23504925 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with no intervention.
Number of subjects: 54
Study 21315678 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month moderate-intensity physical activity (3 times per week at gym and 3 times per week on their own)
Number of subjects: 96
Study 21315678 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 96
Study 19817885 — intervention group
Group type: EXPERIMENTAL
Intervention: 27 tablets of 10 mg rizatriptan ODT per month
Number of subjects: 197
Study 19817885 — intervention group
Group type: COMPARATOR
Intervention: 9 tablets of 10 mg rizatriptan ODT per month
Number of subjects: 197
Study 17766654 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy for women with endocrine-responsive disease
Number of subjects: 0
Study 17766654 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study 17766654 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for postmenopausal women with endocrine nonresponsive early breast cancer
Number of subjects: 0
Study 15001822 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 178 mg
Number of subjects: 50
Study 15001822 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (BUP) 150 mg
Number of subjects: 50
Study 15001822 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 50
Study 15568531 — intervention group
Group type: COMPARATOR
Intervention: Club foot
Number of subjects: 0
Study 11443512 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times a day plus psyllium mucilloid 6.0 g
Number of subjects: 60
Study 11443512 — intervention group
Group type: COMPARATOR
Intervention: Orlistat 120 mg three times a day plus placebo
Number of subjects: 60
Study 11443512 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus orlistat 120 mg three times a day
Number of subjects: 60
Study 11443512 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium plus orlistat 120 mg three times a day
Number of subjects: 60
Study 11443512 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B) with orlistat
Number of subjects: 60
Study 9212009 — intervention group
Group type: EXPERIMENTAL
Intervention: PA radiotherapy
Number of subjects: 0
Study 9212009 — intervention group
Group type: EXPERIMENTAL
Intervention: DL radiotherapy
Number of subjects: 0
Study 8231168 — intervention group
Group type: COMPARATOR
Intervention: HSV
Number of subjects: 120
Study 8231168 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV with patch
Number of subjects: 120
Study 8231168 — intervention group
Group type: COMPARATOR
Intervention: Control (subcutaneous infusion of pentagastrin and carbachol)
Number of subjects: 120
Study 3306780 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf lung surfactant extract (CLSE) 90 mg by intratracheal instillation
Number of subjects: 2
Study 3306780 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2
Study 29395119 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (RBZ) 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP)
Number of subjects: 87
Study 29395119 — intervention group
Group type: COMPARATOR
Intervention: Panretinal photocoagulation (PRP) monotherapy
Number of subjects: 87
Study 27737311 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) combined with cognitive training (N-back and sequence learning tasks)
Number of subjects: 9
Study 27737311 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (device turned off after 60 seconds)
Number of subjects: 9
Study 25711327 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS) for self-assessment of overall current health
Number of subjects: 4631
Study 25711327 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-Form 12-Item Version 2 Health Survey (SF-12V2)
Number of subjects: 4631
Study 25711327 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Health Component Summary (PCS)
Number of subjects: 4631
Study 25711327 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Health Component Summary (MCS)
Number of subjects: 4631
Study 23088936 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nifekalant (0.3mg/kg)
Number of subjects: 110
Study 23088936 — intervention group
Group type: COMPARATOR
Intervention: No intravenous nifekalant (no-AAD group)
Number of subjects: 110
Study 23088936 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study 21406472 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus trastuzumab (L+T)
Number of subjects: 0